• Daesung Microbiological Labs corrected its government procurement supply contract disclosure as the contract term ended on 2026-09-30.
• Final executed contract value was KRW 1.62 billion, revised from KRW 3.98 billion previously disclosed as the maximum possible amount.
• Contract size was revised to 6.81% of 2024 revenue, down from 16.70%.
• The contract, signed 2025-10-14, covered supply of foot-and-mouth disease vaccines to Korea’s Public Procurement Service.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Daesung Microbiological Labs. Co. Ltd. published the original content used to generate this news brief via DART, the regulatory disclosure system operated by the South Korea Financial Supervisory Service (FSS) (Ref. ID: 20260930900583), on September 30, 2026, and is solely responsible for the information contained therein.